Resolvin E1 is a novel anti-inflammatory and anti-fibrotic lipid mediator for the treatment of chronic kidney disease.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/606400

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project will ascertain whether a naturally occurring compound, Resolvin E1 with potent anti-inflammatory properties, can effectively halt the progression of experimental kidney disease. We will also test whether Resolvin E1 can exert other potential benefits in suppressing progressive fibrosis of the kidney. The outcome of this study will allow us to evaluate the therapeutical potential of Resolvin E1 for the treatment of acute and chronic kidney diseases.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $519,246.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anti-inflammatory | anti-inflammatory agent | experimental glomerulonephritis | fibrosis | glomerular inflammation | glomerulosclerosis | kidney | progressive renal diseases | renal interstitial fibrosis

Related Links